NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 262 filers reported holding NEKTAR THERAPEUTICS in Q2 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $282,000 | -15.6% | 15,819 | +2.2% | 0.01% | -8.3% |
| Q4 2019 | $334,000 | -29.7% | 15,485 | +9.5% | 0.01% | -36.8% |
| Q1 2019 | $475,000 | +4.4% | 14,146 | +2.1% | 0.02% | -13.6% |
| Q4 2018 | $455,000 | -42.7% | 13,857 | +6.3% | 0.02% | -33.3% |
| Q3 2018 | $794,000 | +792.1% | 13,033 | +612.6% | 0.03% | +725.0% |
| Q2 2018 | $89,000 | -95.4% | 1,829 | -94.3% | 0.00% | -89.7% |
| Q4 2017 | $1,933,000 | +136.6% | 32,367 | -5.0% | 0.04% | +129.4% |
| Q3 2017 | $817,000 | +24.5% | 34,053 | +1.5% | 0.02% | +13.3% |
| Q2 2017 | $656,000 | +203.7% | 33,545 | +264.6% | 0.02% | +275.0% |
| Q1 2017 | $216,000 | – | 9,201 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |